PDGFRA and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, imatinib, a well-known anticancer drug for chronic myeloid leukemia, has also been shown to inhibit the iCAFs marker PDGFRA to suppress angiogenesis in cervical carcinoma [61].